AstraZeneca (AZN)
NASDAQ: AZN
· Real-Time Price · USD
67.61
0.31 (0.46%)
At close: May 09, 2025, 3:59 PM
67.73
0.18%
After-hours: May 09, 2025, 05:49 PM EDT
AstraZeneca Revenue Breakdown
| Period Ending | Dec 31, 2023 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2019 |
|---|---|---|---|---|---|
| Enhertu Revenue | 955M | 15M | 11M | 13M | 389M |
| Enhertu Revenue Growth | +6266.67% | +36.36% | -15.38% | -96.66% | n/a |
| Bevespi Revenue | 43M | 163M | 53M | 56M | 141M |
| Bevespi Revenue Growth | -73.62% | +207.55% | -5.36% | -60.28% | n/a |
| Breztri Revenue | 514M | 331M | 185M | 375M | 377M |
| Breztri Revenue Growth | +55.29% | +78.92% | -50.67% | -0.53% | n/a |
| Brilinta Revenue | 993M | 43M | 62M | 95M | 167M |
| Brilinta Revenue Growth | +2209.30% | -30.65% | -34.74% | -43.11% | n/a |
| Bydureon Revenue | 120M | 653M | 396M | 280M | 267M |
| Bydureon Revenue Growth | -81.62% | +64.90% | +41.43% | +4.87% | n/a |
| Calquence Revenue | 1.86B | 17M | 54M | 3M | 338M |
| Calquence Revenue Growth | +10847.06% | -68.52% | +1700.00% | -99.11% | n/a |
| Daliresp/Daxas Revenue | 37M | 67M | 18M | 732M | 283M |
| Daliresp/Daxas Revenue Growth | -44.78% | +272.22% | -97.54% | +158.66% | n/a |
| Farxiga Revenue | 4.46B | 1.5B | 275M | 320M | 393M |
| Farxiga Revenue Growth | +196.21% | +447.27% | -14.06% | -18.58% | n/a |
| Fasenra Revenue | 1.15B | 406M | 230M | 105M | 116M |
| Fasenra Revenue Growth | +182.51% | +76.52% | +119.05% | -9.48% | n/a |
| Faslodex Revenue | 219M | 78M | 5M | 604M | 333M |
| Faslodex Revenue Growth | +180.77% | +1460.00% | -99.17% | +81.38% | n/a |
| FluMist Revenue | 213M | 1.08B | 374M | 39M | 585M |
| FluMist Revenue Growth | -80.20% | +187.70% | +858.97% | -93.33% | n/a |
| Imfinzi Revenue | 3.16B | 46M | 20M | 588M | 784M |
| Imfinzi Revenue Growth | +6771.74% | +130.00% | -96.60% | -25.00% | n/a |
| Kanuma Revenue | 125M | 80M | 47M | 336M | 197M |
| Kanuma Revenue Growth | +56.25% | +70.21% | -86.01% | +70.56% | n/a |
| Koselugo Revenue | 251M | 100M | 39M | 99M | 20M |
| Koselugo Revenue Growth | +151.00% | +156.41% | -60.61% | +395.00% | n/a |
| Lokelma Revenue | 312M | 717M | 312M | 167M | 64M |
| Lokelma Revenue Growth | -56.49% | +129.81% | +86.83% | +160.94% | n/a |
| Lynparza Revenue | 2.09B | 248M | 30M | 51M | 96M |
| Lynparza Revenue Growth | +744.35% | +726.67% | -41.18% | -46.88% | n/a |
| Nexium Revenue | 697M | 54M | 1M | 680M | n/a |
| Nexium Revenue Growth | +1190.74% | +5300.00% | -99.85% | n/a | n/a |
| Oncology, Others Revenue | 170M | 65M | 22M | 1.31B | n/a |
| Oncology, Others Revenue Growth | +161.54% | +195.45% | -98.32% | n/a | n/a |
| Onglyza Revenue | 162M | 53M | 6M | 244M | n/a |
| Onglyza Revenue Growth | +205.66% | +783.33% | -97.54% | n/a | n/a |
| Other, Others Revenue | 178M | 124M | 15M | 1M | n/a |
| Other, Others Revenue Growth | +43.55% | +726.67% | +1400.00% | n/a | n/a |
| Pulmicort Revenue | 589M | 73M | 50M | 24M | n/a |
| Pulmicort Revenue Growth | +706.85% | +46.00% | +108.33% | n/a | n/a |
| Roxadustat Revenue | 198M | 68M | 223M | n/a | n/a |
| Roxadustat Revenue Growth | +191.18% | -69.51% | n/a | n/a | n/a |
| Saphnelo Revenue | 212M | 164M | 574M | n/a | n/a |
| Saphnelo Revenue Growth | +29.27% | -71.43% | n/a | n/a | n/a |
| Seloken/Toprol-XL Revenue | 476M | 814M | 193M | n/a | n/a |
| Seloken/Toprol-XL Revenue Growth | -41.52% | +321.76% | n/a | n/a | n/a |
| Soliris Revenue | 2.33B | 300M | 222M | n/a | n/a |
| Soliris Revenue Growth | +677.00% | +35.14% | n/a | n/a | n/a |
| Strensiq Revenue | 852M | 600M | 2M | n/a | n/a |
| Strensiq Revenue Growth | +42.00% | +29900.00% | n/a | n/a | n/a |
| Symbicort Revenue | 1.76B | 87M | 513M | n/a | n/a |
| Symbicort Revenue Growth | +1925.29% | -83.04% | n/a | n/a | n/a |
| Synagis Revenue | 459M | 1.49B | 1.6B | n/a | n/a |
| Synagis Revenue Growth | -69.22% | -7.10% | n/a | n/a | n/a |
| Tagrisso Revenue | 4.31B | 4.38B | 36M | n/a | n/a |
| Tagrisso Revenue Growth | -1.69% | +12072.22% | n/a | n/a | n/a |
| Total Oncology Revenue | 12.76B | 301M | 3M | n/a | n/a |
| Total Oncology Revenue Growth | +4140.20% | +9933.33% | n/a | n/a | n/a |
| Total Other medicines Revenue | 875M | 28M | 18M | n/a | n/a |
| Total Other medicines Revenue Growth | +3025.00% | +55.56% | n/a | n/a | n/a |
| Vaxzevria Revenue | n/a | 233M | 23M | n/a | n/a |
| Vaxzevria Revenue Growth | -100.00% | +913.04% | n/a | n/a | n/a |
| Zoladex Revenue | 719M | 45M | 1M | n/a | n/a |
| Zoladex Revenue Growth | +1497.78% | +4400.00% | n/a | n/a | n/a |
| Andexxa Revenue | 137M | 3M | n/a | n/a | n/a |
| Andexxa Revenue Growth | +4466.67% | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|
| Asia, Africa And Australasia Revenue | 11.95B | 14.37B | 13.65B |
| Asia, Africa And Australasia Revenue Growth | -16.88% | +5.30% | n/a |
| Australia Revenue | 390M | 571M | 6.79B |
| Australia Revenue Growth | -31.70% | -91.59% | n/a |
| Canada Revenue | 967M | 1.17B | 14.89B |
| Canada Revenue Growth | -17.07% | -92.17% | n/a |
| China Revenue | 5.87B | 5.74B | 1.21B |
| China Revenue Growth | +2.25% | +376.20% | n/a |
| Europe Revenue | 9.72B | 8.91B | n/a |
| Europe Revenue Growth | +9.16% | n/a | n/a |
| France Revenue | 1.15B | 1.11B | n/a |
| France Revenue Growth | +4.07% | n/a | n/a |
| Italy Revenue | 813M | 735M | n/a |
| Italy Revenue Growth | +10.61% | n/a | n/a |
| Japan Revenue | 3.64B | 3.99B | n/a |
| Japan Revenue Growth | -8.68% | n/a | n/a |
| Other, Europe Revenue | 3.11B | 2.71B | n/a |
| Other, Europe Revenue Growth | +14.93% | n/a | n/a |
| Spain Revenue | 847M | 738M | n/a |
| Spain Revenue Growth | +14.77% | n/a | n/a |
| Sweden Revenue | 1.7B | 1.72B | n/a |
| Sweden Revenue Growth | -0.99% | n/a | n/a |
| The Americas Revenue | 20.77B | 20.13B | n/a |
| The Americas Revenue Growth | +3.20% | n/a | n/a |
| Uk Revenue | 3.37B | 996M | n/a |
| Uk Revenue Growth | +238.15% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 5.55B | 5.29B | 5.06B | 4.63B | 3.98B | 4.93B | 5.12B | 4.19B | 4.78B | 3.29B | 4.81B | 4.96B | 5.24B | 2.99B | 3.2B | 3.03B | 3.32B | 2.27B | 2.74B | 2.81B | 3.09B | 3.25B | 3.02B | 2.59B | 2.69B | 2.5B | 2.63B | 2.54B | 3.16B | 2.57B | 2.43B | 2.38B | 1.47B | 2.48B | 3.14B | 2.65B | 2.77B | 2.76B | 3.05B | 2.88B |
| Selling, General, and Administrative Revenue Growth | +5.01% | +4.49% | +9.31% | +16.24% | -19.19% | -3.67% | +22.04% | -12.23% | +45.42% | -31.70% | -3.12% | -5.27% | +75.52% | -6.72% | +5.71% | -8.77% | +46.21% | -17.12% | -2.39% | -9.25% | -4.86% | +7.47% | +16.67% | -3.75% | +7.89% | -5.28% | +3.82% | -19.76% | +22.93% | +5.88% | +2.23% | +61.81% | -40.74% | -21.13% | +18.69% | -4.30% | +0.33% | -9.57% | +6.05% | n/a |
| Research and Development Revenue | 4.68B | 3.12B | 3.01B | 2.78B | 3.07B | 2.58B | 2.67B | 2.61B | 2.63B | 2.36B | 2.55B | 2.13B | 2.58B | 2.15B | 1.83B | 1.71B | 1.72B | 1.45B | 1.39B | 1.39B | 2.07B | 1.33B | 1.36B | 1.27B | 2.01B | 1.28B | 1.36B | 1.28B | 1.55B | 1.4B | 1.35B | 1.45B | 1.54B | 1.4B | 1.47B | 1.48B | 1.75B | 1.43B | 1.47B | 1.36B |
| Research and Development Revenue Growth | +50.14% | +3.56% | +8.08% | -9.44% | +18.92% | -3.11% | +2.14% | -0.53% | +11.37% | -7.42% | +19.36% | -17.45% | +20.07% | +17.66% | +6.77% | -0.35% | +18.31% | +4.61% | +0.07% | -33.01% | +56.02% | -2.06% | +7.11% | -37.08% | +57.31% | -6.09% | +6.49% | -17.54% | +10.47% | +4.08% | -7.16% | -5.83% | +10.06% | -4.30% | -1.01% | -15.23% | +22.18% | -2.52% | +8.11% | n/a |
| Sales and Marketing Revenue | 143M | 145M | 132M | 135M | 17.83B | 4.93B | 5.12B | 4.19B | 4.78B | 3.29B | 4.81B | 4.96B | 5.24B | 2.99B | 3.2B | 3.03B | 3.32B | 2.27B | 2.74B | 2.81B | 3.09B | 3.25B | 3.02B | 2.59B | 2.69B | 2.5B | 2.63B | 2.54B | 3.16B | 2.57B | 2.43B | 2.38B | 1.47B | 2.48B | 3.14B | 2.65B | 2.77B | 2.76B | 3.05B | 2.88B |
| Sales and Marketing Revenue Growth | -1.38% | +9.85% | -2.22% | -99.24% | +261.70% | -3.67% | +22.04% | -12.23% | +45.42% | -31.70% | -3.12% | -5.27% | +75.52% | -6.72% | +5.71% | -8.77% | +46.21% | -17.12% | -2.39% | -9.25% | -4.86% | +7.47% | +16.67% | -3.75% | +7.89% | -5.28% | +3.82% | -19.76% | +22.93% | +5.88% | +2.23% | +61.81% | -40.74% | -21.13% | +18.69% | -4.30% | +0.33% | -9.57% | +6.05% | n/a |